EpicentRx

Biotechnology ResearchCalifornia, United States11-50 Employees

EpicentRx, Inc. is a clinical-stage biotechnology company focused on developing therapies and devices that aim to improve the ease of treatment, reduce side effects, and alleviate symptoms across cancer and inflammatory disorders. Its lead program includes a direct NLRP3 inhibitor known as RRx-001 (nibrozetone) and an oncolytic adenovirus therapy enhanced with a TGF-β trap, with the latter advancing in Phase 2 trials and the former in Phase 3. The company also markets a device called eLOOP, reflecting its broader interest in medical technologies alongside immuno-oncology approaches. Based in La Jolla, California, EpicentRx operates in a research-driven space within biotechnology, pursuing collaborations and partnerships to explore combinations and applications of its therapies in cancer and neurodegenerative disease contexts. Recent developments include naming changes for RRx-001 as nibrozetone in the wake of regulatory designations and Fast Track status, alongside ongoing clinical activities. The company positions itself as an innovation-focused entity seeking to address unmet needs in oncology and related inflammatory conditions through its integrated drug and device portfolio.

Sign up for free to view info

Email Format Employee directory